FEATURING CONTENT PRODUCED IN PARTNERSHIP WITH…
Viral vs Non-Viral Vectors
AS GENE THERAPIES EXPAND THEIR CLINICAL DEVELOPMENT AND THERAPEUTIC REACH BIOTECH’S ARE ALWAYS LOOKING FOR BETTER WAYS OF TACKLING THE BIGGEST HURDLE IN GENE THERAPY – THE SAFE AND EFFICIENT DELIVERY OF THE GENETIC MATERIAL TO PATIENTS. IN THIS BLOG POST WE LOOK AT THE PROS AND CONS OF DELIVERY VIA VIRAL VS NON-VIRAL VECTORS.
Why all the Attention on Vectors?
Gene therapies have gained much attention in recent years, with their transformative potential recognized by investors and developers alike. The rise of gene therapies has created a debate – on whether to use viral or non-viral vectors to deliver this genetic material to patient cells.
Designers, developers, and manufacturers choose which of these two vector variations to integrate into gene therapy production based on three main factors:
- Vector safety
- Target efficiency
- Feasibility
According to Global Data, there are currently 4 approved gene therapies and 3 gene therapy products in the pre-registration stages.
15 products are currently under Phase III investigation for a range of indications including hematological disorders, ophthalmology, immunology, and infectious diseases, and, a further 277 gene therapies are in Phase II clinical trials.
With the evidential clinical success of gene therapies growing, so does the interest in vectors. So which should you be using and why?
Use the slider below to navigate through content focused on different vectors for gene therapies.
Would you like to feature in our future content? Please contact the team via team@phacilitate.com
AS GENE THERAPIES EXPAND THEIR CLINICAL DEVELOPMENT AND THERAPEUTIC REACH BIOTECH’S ARE ALWAYS LOOKING FOR BETTER WAYS OF TACKLING THE BIGGEST HURDLE IN GENE THERAPY – THE SAFE AND EFFICIENT DELIVERY OF THE GENETIC MATERIAL TO PATIENTS. IN THIS BLOG POST WE LOOK AT THE PROS AND CONS OF DELIVERY VIA VIRAL VS NON-VIRAL VECTORS.
Why all the Attention on Vectors?
Gene therapies have gained much attention in recent years, with their transformative potential recognized by investors and developers alike. The rise of gene therapies has created a debate – on whether to use viral or non-viral vectors to deliver this genetic material to patient cells.
Designers, developers, and manufacturers choose which of these two vector variations to integrate into gene therapy production based on three main factors:
- Vector safety
- Target efficiency
- Feasibility
According to Global Data, there are currently 4 approved gene therapies and 3 gene therapy products in the pre-registration stages.
15 products are currently under Phase III investigation for a range of indications including hematological disorders, ophthalmology, immunology, and infectious diseases, and, a further 277 gene therapies are in Phase II clinical trials.
With the evidential clinical success of gene therapies growing, so does the interest in vectors. So which should you be using and why?
Use the slider below to navigate through content focussed on different vectors for gene therapies.
Would you like to feature in our future content? Please contact the team via team@phacilitate.com
Feature Exclusives
